Latest Content

Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.

The FDA approved Imfinzi with chemotherapy for adults with resectable gastric or gastroesophageal junction adenocarcinoma.

Surviving breast cancer changes the way you see your body. Every ache, every spot, every unfamiliar sensation becomes a quiet question: “Could it be coming back?”

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.

An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.

I share how the holidays feel different after loss and how grief, love and gratitude can coexist as I navigate this season with gentleness and care.

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Imbruvica plus R-MPV led to high response rates and was tolerable for patients with newly diagnosed primary central nervous system lymphoma.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Eflornithine plus Gleostine was associated with superior overall survival and progression-free survival in grade 3 IDH-mutated astrocytoma.